World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   1400 records for 330 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusMain ID Public TitleDate of Registration
Not recruitingNCT02748213
A Study of Trastuzumab (Herceptin) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
20/04/2016
AuthorisedEUCTR2009-010110-30-HU
The effect and long-term safety of MK-0887A in children with asthma 29/02/2016
AuthorisedEUCTR2015-004326-34-SE
Trial 2 to Assess MK-8342B Treatment Efficacy-Safety in Dysmenorrhea
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2015-004326-34-PLTrial to Assess MK-8342B Treatment Efficacy-Safety in Dysmenorrhea25/01/2016
RecruitingNCT02668822Efficacy and Safety of Etonogestrel + 17ß-Estradiol Vaginal Ring in Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)26/01/2016
08/12/2015
RecruitingNCT02567006
SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala
30/09/2015
Not recruitingNCT02563054
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
28/09/2015
AuthorisedEUCTR2015-002553-35-GB
Study of efficacy and safety of QAW039 in patients with severe asthma inadequately controlled with standard of care asthma treatment. 01/09/2015
AuthorisedEUCTR2014-002208-26-NO
Study to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-002208-26-NLStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.20/10/2015
AuthorisedEUCTR2014-002208-26-ESStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.13/10/2015
AuthorisedEUCTR2014-002208-26-SEStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.27/08/2015
AuthorisedEUCTR2014-002208-26-DKStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.21/09/2015
AuthorisedEUCTR2014-002208-26-DEStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.07/09/2015
AuthorisedEUCTR2014-002208-26-HUStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.22/10/2015
AuthorisedEUCTR2014-002208-26-FIStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.15/09/2015
AuthorisedEUCTR2014-002208-26-PLStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.15/12/2015
AuthorisedEUCTR2014-002208-26-CZStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.14/01/2016
AuthorisedEUCTR2014-002208-26-ATStudy to assess the efficacy and safety of a new contraceptive vaginal ring containing etonogestrel and estradiol and a marketed oral contraceptive pill containing levonorgestrel and ethinyl-estradiol.24/09/2015
26/08/2015
AuthorisedEUCTR2015-001020-27-DE
A Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer. 20/08/2015
AuthorisedEUCTR2015-001020-27-SE
A Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer.
20/08/2015
AuthorisedEUCTR2015-000114-22-EE
Evaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2015-000114-22-LVEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD27/08/2015
AuthorisedEUCTR2015-000114-22-HUEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD16/09/2015
AuthorisedEUCTR2015-000114-22-ESEvaluation of the efficacy and safety of QVA149 (110/50 ?g o.d.) vs tiotropium (18 ?g o.d.) + salmeterol/fluticasone propionate FDC (50/500 ?g b.i.d.) in patients with moderate to severe COPD30/10/2015
AuthorisedEUCTR2015-000114-22-LTEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD31/08/2015
AuthorisedEUCTR2015-000114-22-ATEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD05/11/2015
AuthorisedEUCTR2015-000114-22-SKEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD22/09/2015
RecruitingNCT02603393Evaluation of the Efficacy and Safety of QVA149 (110/50 µg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD17/09/2015
AuthorisedEUCTR2015-000114-22-DEEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD10/09/2015
AuthorisedEUCTR2015-000114-22-HREvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD01/02/2016
AuthorisedEUCTR2015-000114-22-GREvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD29/01/2016
AuthorisedEUCTR2015-000114-22-NLEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD18/08/2015
AuthorisedEUCTR2015-000114-22-DKEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD16/09/2015
AuthorisedEUCTR2015-000114-22-PLEvaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD18/12/2015
11/08/2015
    
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history